Health Care Sector Itolizumab Phase 3 Clinical Trials to Begin in US, Mexico and Brazil Itolizumab, a monoclonal antibody developed by the Center of Molecular Immunology (CIM) in collaboration with Biocon, India’s largest pharmaceutical company, received authorization to begin... David UrraNovember 9, 2020